Real‐World Outcomes of Immune Checkpoint Inhibitors in Head and Neck Squamous Cell Carcinoma: Analyzing Patient‐Specific Factors Influencing Survival and Response Rate

Ähnliche Einträge

• Preventing Free Flap Complications: Key Factors to Keep in Mind
  von: Jonas Kornmann, et al.
  Veröffentlicht: (2025)
• Risk Factors for Progressive Disease After Immune Checkpoint Inhibitor Therapy in Head and Neck Squamous Cell Carcinoma
  von: Seo Yoon Jang, et al.
  Veröffentlicht: (2025)
• Safety and Efficacy of Intra‐Arterial Chemotherapy Combined With Immune Checkpoint Inhibitors in the Treatment of Advanced Head and Neck Squamous Cell Carcinoma
  von: Chao Yang, et al.
  Veröffentlicht: (2025)
• A Comprehensive Immune Checkpoint Phenotype Predicts Response and Survival to PD ‐1 Blockade in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
  von: Mathias Fiedler, et al.
  Veröffentlicht: (2026)
• Response to Letter to the Editor: Fully COVID ‐19 Vaccinated Status Enhanced the Efficacy of Immune Checkpoint Inhibitors in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
  von: Chien‐Chung Wang, et al.
  Veröffentlicht: (2026)